共 20 条
[1]
Jemal A(2011)Global cancer statistics CA Cancer J Clin 61 69-90
[2]
Siegel RL(2015)Cancer statistics, 2015 CA Cancer J Clin 65 5-29
[3]
Miller KD(2005)Extending survival with chemotherapy in metastatic breast cancer Oncologist 10 20-29
[4]
Jemal A(2015)Targeted therapies for ER+/HER2- metastatic breast cancer BMC med 13 137-3200
[5]
O'Shaughnessy J(2004)Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the international letrozole breast cancer group J Clin Oncol 22 3199-6
[6]
Yamamoto-Ibusuki M(2012)Disease burden and treatment outcomes in second-line therapy of patients with estrogen receptor-positive (ER+) advanced breast cancer: a review of the literature Breast 21 701-1545
[7]
Arnedos M(2014)Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012 Curr med res Opin 30 1537-1118
[8]
Andre F(2015)Everolimus-based therapy versus chemotherapy among patients with HR+/HER2- metastatic breast cancer: comparative effectiveness from a chart review study Int J Breast Cancer 2015 240750-3757
[9]
Buzdar AU(2015)Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US Exp Hematol Oncol 4 31-511
[10]
Boswell KA(2012)Tumor hormone/HER2 receptor status and pharmacologic treatment of metastatic breast cancer in Western Europe Curr med res Opin 28 1111-6335